American Journal of Clinical Medicine Research
ISSN (Print): 2328-4005 ISSN (Online): 2328-403X Website: http://www.sciepub.com/journal/ajcmr Editor-in-chief: Dario Galante
Open Access
Journal Browser
Go
American Journal of Clinical Medicine Research. 2016, 4(2), 19-24
DOI: 10.12691/ajcmr-4-2-1
Open AccessArticle

Chronic Hepatitis C Virus Infection: Epidemiology, Treatment and Barriers of Management in Non Type 1 Genotypes infection

Shagufta Ahsan1,

1Complete Care Health Network, 53 S. Laurel Street, Bridgeton, NJ 08302, The USA

Pub. Date: May 30, 2016

Cite this paper:
Shagufta Ahsan. Chronic Hepatitis C Virus Infection: Epidemiology, Treatment and Barriers of Management in Non Type 1 Genotypes infection. American Journal of Clinical Medicine Research. 2016; 4(2):19-24. doi: 10.12691/ajcmr-4-2-1

Abstract

Chronic Hepatitis C (HCV) infection occurs in more than 130 to 150 million individuals world wide. Twenty percent of patients chronically infected with HCV progress to cirrhosis. Other than cirrhosis, Chronic HCV infection is strongly associated with liver cancer and end-stage liver disease requiring transplantation. However, as with the approval of the fisrt generation protease inhibitors telaprevir and boceprevir, we see significant progress in the treatment of chronic hepatitis c infection. however this has benefited many but not all patients with HCV infection as protease inhibitors have never been approved for genotype 2 and 3. No direct acting antiviral agents have ever been approved until recently. Very recently sofosbuvir, a direct acting antiviral agent which is a nucleotide polymerase inhibitor, has been approved for genotypes 2, 3, (and genotypes 1 and 4), where as multiple direct acting agents are approved and used for genotype 1 which includes but is not limited to Simeprevir. Now patients with genotype 3 have emerged among the hardest to treat. The reason behind this treatment failure of genotype 3 infections is that genotype 3 still remains a challenge to the efficacy of even newer regimen Also genotype 3 is associated with a more rapid progression of the disease. In addition, genotype 4 is increasing in Europe. Thus we want to emphasize the ongoing need for new, simpler therapeutics using direct –acting antivirals that target various stages of the HCV lifecycle to eradicate HCV without concomitant INF.

Keywords:
chronic hepatitis C non type 1 genotypes epidemiology direct acting anti virals sofosbuvir

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  World Health Organization. Who face sheet 164. 2014 http:/ www. Who.int/media centre.
 
[2]  Gane EJ, Stedman A Ctherine A, Hyland, Robert H et al. Nucleotide polymerase inhibitir sofosbuvir plus ribavirin for hepatitis C. NEJM 2013; 368(1) 34-44.
 
[3]  Jacobson IM, Mc HitchinsonTG, Dusheiks G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. NEJM 2011: 364; 2405-16.
 
[4]  Pordad F, Mc cone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection NEJM 2011, 364: 1195-206.
 
[5]  www.businesswire.ca.
 
[6]  EASL Clinical Practice Guidelines: Management of hepatitis C virus infect. European association for the study of liver disease. Journal of Hepatology. 2014, Vol 60. 392-420.
 
[7]  www. Easl.eu.
 
[8]  drkney.com.
 
[9]  Das BR, Kundu B, Khandapkar R, Sahni S, et al. Geographical distribution of hepatitis C virus genotypes in india. Indian J Pathology Microbiology 2002: 45.
 
[10]  Frank c, Mohamed MK, Strickland GT, Lavanchy D. the role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. lancet 2000; 355: 887-891.
 
[11]  Rao, Naficy AB, Darwish MA, Darwish NM, et al. Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt. BMC infect Dis 2002; 2: 29.
 
[12]  Khattab MA, Ferenci P, Hadziyannis SJ, et al. Management of hepatitis C virus genotype 4: recommendation of an internal expert panel. J Hepatol 2011; 54: 1250-1262.
 
[13]  Wantuck JM, Ahmed a, Nguyen MH, et al. Review article: The epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Alimen Pharmacol ther 2014; 39: 137-147.
 
[14]  Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6 Alimen Pharmacol ther 2014.
 
[15]  Guerra J, garenee M, Mohamed MK, Fontanet A, et al. HCV burden of infection in Egypt; results froma nationwide survey. J Viral Hepat 2012: 19: 560-567.
 
[16]  Alter, M.J 1995. Epidemiology of hepatitis C in the West. semin. Liver 1: 5-14.
 
[17]  Smuts HE, Kannemeyer J. Genotyping of hepatitis C virus infection in South Africa. J Clin microbial. 1995; 33: 1679-81.
 
[18]  Huytt, abek. Molecular epidemiology of hepatitis B and C virus infections in Asia. Pediatrics International. 2004; 46: 223-230.
 
[19]  jcm.asm.org.
 
[20]  Gerberding, J. L 1994. Incidence and prevalence of HIV, HBV, HCV, and CMV among health care personel at risk for blood exposure: Final report from a longitudinal study. J. infect. Dis. 170: 1410-1417.
 
[21]  Kiyosawa, K, et al. 1991. Hepatitis C in hospital employees with needle stick injuries. Ann Internal Med. 115: 367-369.
 
[22]  Mitsu, T, et al. 1992. Hepatitis C virus infection in medical personnel after needle stick accident. Hepatology 16; 1109-1114.
 
[23]  Lib.bioinfo.pl.
 
[24]  C. Mathel, G. Robaelys, P. Vandamme. F. Buntix. Prevalence of hepatitis C in drug users in Fanders: Determinants and geographic differences. Epidemiol Infec (2005), 1333, 127 -136.
 
[25]  Goldberg d, Mcintyre Pg, Smith R, et al. Hepatitis c virus among high and low risk pregnanat woman in Dundee: Unlinked anonymous testing, Br. J Obstet Gynecol 2001; 108: 365-370.
 
[26]  www.medsci.org.
 
[27]  Ni u MT, coleman PJ, alter MJ. Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and staff. am J Kidney Dis 1993; 22: 568-573.
 
[28]  conlon PJ, walshe JJ, smyth EG, mc Namara EB, et al. Lower prevalence of anti hepatitis C antibody in dialysis and renal transplant patients in Irland. Irish J Med Sci 1993: 162; 145-147
 
[29]  Medin C, allander t, Roll M, Jacobson SH. Seroconversion to hepatitis c virus in dialysis patients: a retrospective and prospective study. nepron 1993; 65: 40-45.
 
[30]  Hardy NM, sandroni S, danielson S, wilson WJ. antibody to hepatitis C virus increases with time on hemodialysis. Clin Nephrol 1992; 38: 44-48.
 
[31]  Nordenfelt E, Lofgren B, Widell A, hanson BG, Zhagy Y. Hepatitis C virus infection in hemodialysis patients in southern Sweden: Epidemiological, clinical, and diagnostic aspects. J. Med Virol 1993; 40: 266-270.
 
[32]  Qadi, A Abeer, Tamin Hal, Ghada, Anee, et al. Hepatitis b and Hepatitis c virus prevalence among dialysis patients in Bahrain and Saudi Arabia: A survey by serologic and molecular methods. AJIC Vol. 32 no.8.
 
[33]  Angelico M, Tiscone G, Rapicetta m, et al. Hepatitis C virus infection in Italian kidney graft recepients. Changing risk factors and hepatitis c genotypes. Ital J Gastroenterology Hepatology.
 
[34]  Aghemo, Asessio, and Elisabetta Degasperi. Sofosbuvir for the treatment of Chronic hepatitis C: between current evidence and future perspectives. Hepatic Medicine Evidence and Research, 2014.
 
[35]  www.natap.org 33.
 
[36]  Dalgard O, et al. Journal of Hepatology. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virologic response. 2008, 47: 35-43.
 
[37]  Ira Jacobson, MD Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options, NEJM may 16, 2013.
 
[38]  Lawitz E, Mangia Alessandra, Wyles David et al, Sofosbuvir for previously untreated chronic hepatitis C infection. NEJM 368; 20, May 16, 2013.
 
[39]  Ledipasvir and Sofosbuvir for previously treated HCV genotype 1 infection. NEJM April 17, 2014.
 
[40]  www. Businesswire.ca, reference close to 38.
 
[41]  Daclatasvir plus sofosbuvir for HCV infection: An oral combination therapy with high anti viral efficacy. Journal of Hepatology. Accepted manuscript. Accepted date 23 April, 2014.
 
[42]  Hezode Christopher, MD, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment naïve and treatment experienced patients with genotype 4 chronic hepatitis C infection (PEARL -1): a randomized, open label trial. 30 March, 2015.
 
[43]  Ruane PJ, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatology.
 
[44]  www.idsociety.org.
 
[45]  www.hcvguidelines.org.
 
[46]  www.helps-group.it.
 
[47]  Kowdley K, et al, Lawitz E et al, Crespo I et al. Sofosbuvir with pegylated interferon alfa -2a and ribavirin for treatment naïve patients with hepatitis C genotype -1 infection (atomic): An open –label, randomized, multicenter phase 2 trial. lancet 2013; 381: 2100-7.
 
[48]  Alfredo Arredondo Bruce, Osmani Risco Morales. A new Era in the management of the hepatitis C. International Journal of Clinical Medicine, 2014, 5, 660-666.
 
[49]  Virosciencelab.org.
 
[50]  Hagan, H, et al. reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma Syringe exchange program. am J Public Helath. 85: 1531-1537.
 
[51]  Theodore Sy, M. Mazen Jamal Epidemiology of Hepatitis C virus infection. International Journal of Medical sciences. 2006 3(2): 41-46.